Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma

Kelley V. Foyil, Dana A. Kennedy, Laurie E. Grove, Nancy L. Bartlett, Amanda F. Cashen

Research output: Contribution to journal › Letter › peer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma'. Together they form a unique fingerprint.